Tesamorelin has the best-documented body-composition effect of any peptide in the performance conversation. It also has the narrowest approved population and a durability problem nobody puts in the marketing. Both facts are load-bearing.
What the trials actually measured
Tesamorelin was approved in 2010 as Egrifta for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. It remains the only GHRH analog with a live FDA approval.
The registration program ran two randomized double-blind placebo-controlled Phase 3 trials. The primary endpoint was percent change in visceral adipose tissue measured by CT at the L4–L5 level — not weight, not waist circumference, not a DEXA readout. DEXA cannot separate visceral from subcutaneous fat, which is exactly why the trials used CT.
| Trial | VAT change vs. placebo at 26 wks | Notes |
|---|---|---|
| LIPO-010 | −19.6% | LS mean difference |
| CTR-1011 | −11.7% | LS mean difference |
| Pooled (n≈806) | ~−15% | p<0.001 |
| Prespecified threshold | 8% | Minimum clinically meaningful reduction |
Secondary findings included improvements in triglycerides and the total-cholesterol-to-HDL ratio. Separate work has documented reductions in liver fat, which is what drove the off-label interest in metabolic liver disease.
The three caveats that change the decision
1. The population was specific
Every registration-quality trial enrolled adults with HIV-associated lipodystrophy on antiretroviral therapy. That is a distinct metabolic phenotype. Whether a 15% VAT reduction generalizes to a forty-five-year-old lifter with central adiposity from ordinary causes is an open question, not a demonstrated result.
2. It is visceral-selective, not a weight drug
Visceral adipose tissue has higher GH receptor density than subcutaneous fat, which is the mechanistic story for why the effect concentrates where it does. The practical consequence is that the scale may barely move while the CT number changes substantially. If your goal is a number on a scale, this is the wrong tool.
3. The effect is maintenance-dependent
Visceral fat reduction on tesamorelin does not persist after discontinuation in the trial data. That turns a 26-week course into an open-ended commitment if you want to keep the result — and tesamorelin is not cheap. Any cost analysis that models a single cycle is modeling the wrong thing.
The antibody finding
The Egrifta label reports that a majority of treated patients developed anti-tesamorelin IgG antibodies by 26 weeks, with cross-reactivity to endogenous GHRH observed in roughly 60% of those who seroconverted. That sounds alarming and deserves a straight answer: patients with and without antibodies showed similar mean reductions in VAT and similar IGF-1 responses. The immunogenicity is real and documented; the functional consequence in the trial population was not obvious.
Who this is actually for
Someone with imaging or a clinical picture indicating meaningful visceral adiposity, working with a clinician who will monitor IGF-1 and glucose, who understands they are paying for an ongoing effect rather than a one-time result, and who is not expecting it to substitute for training and diet.
Everyone else is likely better served by the unglamorous levers, or by a GLP-1 if the actual problem is total adiposity rather than the visceral compartment specifically.
Prescription evaluation
Frequently Asked
In the pooled Phase 3 analysis of roughly 806 adults with HIV-associated lipodystrophy, CT-measured visceral adipose tissue fell by approximately 15% relative to placebo over 26 weeks. Individual trial estimates ranged from about −11.7% to −19.6%.
It is not a weight-loss drug. The measured endpoint was visceral adipose tissue on CT imaging, not body weight. People expecting scale movement comparable to a GLP-1 are looking at the wrong tool.
The visceral fat reduction is not durable after discontinuation in the trial data. This is a maintenance-dependent effect, which materially changes the long-run cost calculation.
The label reports that a majority of treated patients developed anti-tesamorelin IgG antibodies by 26 weeks, with cross-reactivity to endogenous GHRH in a substantial subset. Notably, patients with and without antibodies had similar mean VAT and IGF-1 responses.
It is legal for a clinician to prescribe off-label, and the mechanism is not population-specific in any obvious way. But there is no registration-quality controlled evidence outside HIV-associated lipodystrophy, and that gap should be priced into the decision honestly.